Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint
Study: Rencarex Treatment Efficacy Increases With CAIX Antigen Density in Tumor Tissue
DSMB Recommends Discontinuing Phase III Perifosine Combination Trial
51% Control Rate Achieved In Phase II Trial of Elderly Patients
Study: Partial Kidney Removal Leads to Greater Survival
Phase IIb Trial of CRLX101 Fails Overall Survival Endpoint
AIDS Cachexia Drug Stabilizes Body Weight, Muscle Mass
Two Children Achieve Remission With CD19 Immunotherapy
Adjuvant Chemotherapy Unneeded In Children with Low-Risk Disease
Study: Oncotype DX Score Can Predict Local Recurrence
BRAF Mutation Testing Classifies Indeterminate FNA Samples
NCI CTEP Approved Trials For the Month of March
FDA Approves Lymphoseek For Imaging Lymph Nodes
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer. - Harold Freeman, a surgeon who championed health equity, dies at 93
Freeman, the father of patient navigation, served as president of ACS and chair of the President’s Cancer Panel - Letai takes a swipe at “ill-informed commentators,” as he lays out his scientific vision for NCI
“To my knowledge, 100% of grants that clear my desk get funded” - Senthil K. Muthuswamy named director of NCI’s Center for Cancer Research
